HRT Financial’s BioNexus Gene Lab BGLC Stock Holding History

HRT Financial’s Portfolio BGLC Stock Details BGLC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$27K	Buy	+14,283	New	+$31.1K	﹤0.01%	3886
2024 Q3	–	Sell	-1,467	Closed	-$6K	–	2425
2024 Q2	$6K	Sell	1,467 -723	-33%	-$4.06K	﹤0.01%	2027
2024 Q1	$15K	Buy	+2,190	New	+$14.4K	﹤0.01%	2033
2023 Q4	–	Sell	-4,547	Closed	-$38K	–	2322
2023 Q3	$38K	Buy	+4,547	New	+$74K	﹤0.01%	2021

Other funds holding BGLC

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

CIAM

Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return

HRT Financial's BGLC Position: Q2 2026 in Review

HRT Financial opened a new position in BioNexus Gene Lab (BGLC) in Q2 2026: 14,283 shares worth $27K. The stake represents ﹤0.01% of the portfolio and ranks #3886 among its holdings. This is a return to the name: HRT Financial previously reported a position in BGLC as recently as Q2 2024.

HRT Financial first reported a position in BGLC in Q3 2023 and has held it in 4 quarters since. The position peaked at $38K in Q3 2023. 3 funds tracked by Wall St. Rank hold BGLC as of Q2 2026.

HRT Financial held 14,283 shares of BioNexus Gene Lab worth $27K as of Q2 2026.
BioNexus Gene Lab was a new HRT Financial position in Q2 2026.
BioNexus Gene Lab made up ﹤0.01% of HRT Financial's portfolio in Q2 2026, its #3886 holding.
HRT Financial first reported a position in BioNexus Gene Lab in Q3 2023 and has held it in 4 quarters since.
HRT Financial's BioNexus Gene Lab position peaked at $38K in Q3 2023.
3 funds tracked by Wall St. Rank held BioNexus Gene Lab as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.